Moxifloxacin cas 151096-09-2

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent. Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."

Properties:

Appearance & Physical State: Almost white crystalling power

Density: 1.408 g/cm3

Boiling Point: 636.4ºC at 760 mmHg

Melting Point: 203-208ºC

Flash Point: 338.7ºC

Refractive Index: 1.633

Vapor Pressure: 4.56E-17mmHg at 25°C

Related Prodcuts:

Moxifloxacin HCL; Fasudil; Fasudil HCL; Pixantrone Maleate; Topotecan Hydrochloride; Irinotecan HCl Trihydrate; Irinotecan; Gemfibrozil; Cicloheximide; Oxaliplatin; Camptothecin; 10-Hydroxycamptothecin; Bendamustine hydrochloride

[1]. Balfour, J.A. and H.M. Lamb, Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000. 59(1): p. 115-39.

[2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.

[3]. Ioannidis, O., et al., Effect of moxifloxacin on the survival, lipid peroxidation and inflammation of immunosuppressed rats with soft tissue infection from Stenotrophomonas maltophilia. Microbiol Immunol, 2013.